Highlights Lupin Limited

Equities

500257

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:56 05/06/2026 BST			5-day change	1st Jan Change
2,268.10 ^INR	+0.86%		-0.19%	+7.39%

06-05	Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments	MT
06-04	Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection	CI

Highlights

06-05	Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments	MT
06-04	Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection	CI
06-03	Lupin Limited and Natco Pharma Limited Receive Approval from U.S. FDA for Eribulin Mesylate Injection	CI
06-01	Lupin Gets US FDA's Nod for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablet	MT
05-29	Lupin Limited Receives Approval From U.S. FDA For Sodium Sulfate, Magnesium Sulfate, And Potassium Chloride Tablets	CI
05-28	Lupin Limited Shares Phase 1 Data On LNP8701 At The ASCO Annual Meeting 2026	CI
05-28	Lupin's Ankleshwar facility receives EIR from U.S. FDA	RE
05-22	Lupin says co receives China approval for oseltamivir phosphate oral suspension	RE
05-18	Lupin Limited Receives Tentative Approval From U.S. FDA For Revefenacin Inhalation Solution	CI
05-15	Lupin Launches New Neuro-Rehabilitation Center in New Delhi, India	MT
05-15	Lupin Limited Expands Access to Advanced Neuro-Rehabilitation Care with New Center in Delhi	CI
05-13	Lupin Limited Receives U.S. FDA Approval for Famotidine Injection, USP	CI
05-13	Lupin receives U.S. FDA approval for famotidine injection, USP	RE
05-08	Lupin's Consolidated Profit Rises in Fiscal Q4	MT
05-07	Lupin Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-07	Lupin Limited Recommends Dividend for the Financial Year Ended March 31, 2026	CI
05-07	Lupin March-quarter consol net profit 14.6 billion rupees	RE
05-05	Lupin Limited Receives U.S. FDA Approval For Glycerol Phenylbutyrate Oral Liquid	CI
05-05	Lupin receives U.S. FDA approval for glycerol phenylbutyrate oral liquid	RE
05-05	Lupin Gets US FDA Nod for Glycerol Phenylbutyrate Oral Liquid	MT
04-22	Lupin Limited Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States	CI
04-17	Lupin Limited Incorporates Wholly Owned Subsidiary in Thailand	CI
04-08	Lupin Limited Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States	CI
04-07	Lupin Limited Announces Approval of Dapagliflozin Tablets in the United States	CI
04-02	Lupin to Up Stake in Philippines Unit	MT